Babatunde O. Oyajobi, MBBS, Ph.D., MBA

Img 8252


Dr. Oyajobi's lab conducts studies aimed at understanding the pathogenesis of cancer-induced bone diseases and specifically, the multiple myeloma-associated bone disease. We are particularly interested in the translation of novel insights into the biology of multiple myeloma-induced bone disease into therapies for patients and employ a variety of complementary in vitro and in vivo approaches. To evaluate efficacy of novel therapeutic agents, we utilize primarily the Radl 5T model of myeloma which replicates many of the features seen in the human disease. In this model, when murine 5TGM1 myeloma cells genetically engineered to express either green fluorescent protein or luciferase are injected intravenously in naïve syngeneic C57BL/kaLwRijHsd mice, they home to the skeleton where they form tumors in the medullary cavities.

Selected Publications

Medina EM, Oberheu K., Polusani SR, Ortega V, Velagaleti GVN, Oyajobi BO. PKA/AMPK signaling in relation to the anti-proliferative effect of adiponectin on multiple myeloma.  Leukemia. 2014.  PMID 24646889.

Dairaghi DJ, Oyajobi BO, Gupta A, McCluskey B, Miao S, Powers JP, Seitz LC, Wang Y, Zeng Y, Zhang P, Schall TJ, Jaen JC. CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease. Blood. 2012 Aug 16;120(7):1449-57. [Highlighted in (i) ‘Inside Blood‘ Commentary, page 1351 of same issue; (ii) Science-Business eXchange SciBX 5(23); (iii) BoneKEy Reports 1:168

Johnson RW, Nguyen MP, Padalecki SS, Grubbs BG, Merkel AR, Oyajobi BO, Matrisian LM, Mundy GR, Sterling JA. TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling. Cancer Res. 2011 Feb 1;71(3):822-31.

Murillo O, Arina A, Hervas-Stubbs S, Gupta A, McCluskey B, Dubrot J, Palazón A, Azpilikueta A, Ochoa MC, Alfaro C, Solano S, Pérez-Gracia JL, Oyajobi BO*, Melero I*. (*Co-Senior Authors). Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma. Clin Cancer Res. 2008 Nov 1;14(21):6895-906.

Oyajobi BO, Muñoz S, Kakonen R, Williams PJ, Gupta A, Wideman CL, Story B, Grubbs B, Armstrong A, Dougall WC, Garrett IR, Mundy GR. Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging. Mol Cancer Ther. 2007 Jun;6(6):1701-8. (Featured in “Molecular Cancer Therapeutics Highlights" of same issue)

Associate Professor

Cell Systems and Anatomy


MBA, University of Texas at Austin, 2007

Ph.D. Human Metabolism & Clinical Biochemistry; University of Sheffield, England 1992

MS, Clinical Biochemistry; University of Leeds, England 1986

MBBS, (M.D. equivalent) University of Lagos, Nigeria 1983



Phone: (210) 567-0909

Research Profile
More Info...